Kintor Pharmaceutical Limited (HKG:9939)
Hong Kong
· Delayed Price · Currency is HKD 4.050
+0.970 (31.49%)
At close: Mar 10, 2026
Kintor Pharmaceutical Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Operating Revenue | 10.98 | 5 | - | - | 34.23 | - | Upgrade
|
| Revenue | 10.98 | 5 | - | - | 34.23 | - | Upgrade
|
| Cost of Revenue | 10.43 | 3.12 | -4.13 | - | - | - | Upgrade
|
| Gross Profit | 0.56 | 1.88 | 4.13 | - | 34.23 | - | Upgrade
|
| Selling, General & Admin | 86.21 | 88.38 | 96.03 | 152.58 | 117.95 | 85.69 | Upgrade
|
| Research & Development | 87.43 | 78.14 | 938.91 | 827.97 | 767.94 | 328.76 | Upgrade
|
| Other Operating Expenses | -18.48 | -19.95 | -7.49 | -11.43 | -16.96 | -14.71 | Upgrade
|
| Operating Expenses | 156.36 | 147.78 | 1,027 | 969.12 | 868.93 | 399.74 | Upgrade
|
| Operating Income | -155.8 | -145.9 | -1,023 | -969.12 | -834.7 | -399.74 | Upgrade
|
| Interest Expense | -6.3 | -9.28 | -9.69 | -8.19 | -2.49 | -3.38 | Upgrade
|
| Interest & Investment Income | 0.81 | 4.21 | 13.08 | 6.88 | 12.05 | 10.42 | Upgrade
|
| Earnings From Equity Investments | -1.91 | -1.43 | 0.05 | -0.57 | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | 2.52 | 3.73 | -3.13 | 16.33 | -17.63 | -118.29 | Upgrade
|
| EBT Excluding Unusual Items | -160.69 | -148.67 | -1,023 | -954.67 | -842.77 | -511 | Upgrade
|
| Gain (Loss) on Sale of Investments | 0 | 0 | 0.49 | 2 | 0.78 | 2.13 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.04 | 0 | 0.01 | -0.62 | -0.11 | 0.64 | Upgrade
|
| Asset Writedown | -6.62 | -6.61 | -46.36 | - | - | - | Upgrade
|
| Pretax Income | -167.34 | -155.27 | -1,069 | -953.28 | -842.1 | -508.23 | Upgrade
|
| Income Tax Expense | -0.28 | 0.02 | -8.04 | 1.09 | - | 0.07 | Upgrade
|
| Net Income | -167.07 | -155.29 | -1,061 | -954.37 | -842.1 | -508.3 | Upgrade
|
| Net Income to Common | -167.07 | -155.29 | -1,061 | -954.37 | -842.1 | -508.3 | Upgrade
|
| Shares Outstanding (Basic) | 433 | 431 | 429 | 377 | 356 | 309 | Upgrade
|
| Shares Outstanding (Diluted) | 433 | 431 | 429 | 377 | 356 | 309 | Upgrade
|
| Shares Change (YoY) | 0.58% | 0.39% | 13.94% | 5.66% | 15.21% | 29.24% | Upgrade
|
| EPS (Basic) | -0.39 | -0.36 | -2.47 | -2.53 | -2.36 | -1.64 | Upgrade
|
| EPS (Diluted) | -0.39 | -0.36 | -2.47 | -2.53 | -2.36 | -1.64 | Upgrade
|
| Free Cash Flow | -159.9 | -200.62 | -390.3 | -988.73 | -1,128 | -449.92 | Upgrade
|
| Free Cash Flow Per Share | -0.37 | -0.47 | -0.91 | -2.63 | -3.16 | -1.45 | Upgrade
|
| Gross Margin | 5.05% | 37.58% | - | - | 100.00% | - | Upgrade
|
| Operating Margin | -1418.46% | -2918.00% | - | - | -2438.42% | - | Upgrade
|
| Profit Margin | -1521.00% | -3105.84% | - | - | -2460.04% | - | Upgrade
|
| Free Cash Flow Margin | -1455.79% | -4012.36% | - | - | -3294.09% | - | Upgrade
|
| EBITDA | -137.01 | -132.75 | -1,009 | -956.45 | -827.97 | -396.33 | Upgrade
|
| D&A For EBITDA | 18.79 | 13.15 | 13.85 | 12.68 | 6.73 | 3.42 | Upgrade
|
| EBIT | -155.8 | -145.9 | -1,023 | -969.12 | -834.7 | -399.74 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.